Zdrowie i gospodarka · 14/08/2007

FDA Requests Public Meeting and Input on Osteoarthritis Clinical Development Programs

The US Food and Drug Administration (FDA) is seeking input from interested parties on the clinical development of treatments for osteoarthritis (OA), with a focus on developing new products to prevent and treat the condition. The agency plans to hold a public meeting to discuss OA assessment and trial design, and will consider all submitted information in finalizing its draft guidance.